Abstract: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.
Type:
Grant
Filed:
November 16, 2001
Date of Patent:
June 8, 2004
Assignee:
Research Development Foundation
Inventors:
Charles J. Arntzen, Jordan U. Gutterman
Abstract: The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. The instant invention provides a useful animal model to regulate malonyl-CoA production by ACC2 in the regulation of fatty acid oxidation by muscle, heart, liver and other tissues. They also identify potential inhibitors for studying the mechanisms of fat metabolism and weight control.
Type:
Grant
Filed:
August 14, 2001
Date of Patent:
May 11, 2004
Assignee:
Research Development Foundation
Inventors:
Salih J. Wakil, Martin Matzuk, Lutfi Abu-Elheiga
Abstract: The present invention provides cell culture media and methods useful for determining levels of intracellular function of glutathione or cysteine and for providing biochemical analysis of antioxidant function in human lymphocytes.
Abstract: The present invention provides a method for the in vitro selection of signaling aptamers comprising the steps of synthesizing a DNA pool, the DNA having a random insert of nucleotides of a specific skewed mole ratio; amplifying the DNA pool; transcribing an RNA pool from the amplified DNA using a fluorescently labeled nucleotide; applying the fluorescently labeled RNA pool to an affinity column to remove the high-affinity fluorescent RNA molecules from the fluorescently labeled RNA pool; obtaining a cDNA pool from the high-affinity fluorescent RNA molecules; repeating the amplification and selection steps on the fluorescent RNA molecules and cloning the fluorescent RNA molecules to yield signaling aptamers. Signaling aptamers comprising DNA molecules are also selected for. Also provided is a signaling aptamer that transduces the conformational change upon binding a ligand to a change in fluorescence intensity of the signaling aptamer.
Type:
Application
Filed:
October 16, 2003
Publication date:
May 6, 2004
Applicant:
Research Development Foundation
Inventors:
Andrew D. Ellington, Sulay D. Jhaveri, Manjula Rajendran
Abstract: Tertrapyrrolic macrocycles selected from 5,10,15,20-tetraaryl-porphyrins and 5,10,15-triaryl-corrloes, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, inhibit growth factor (e.g. bFGF, VEGF) receptor tyrosine kinase activity, and are useful for inhibition of cell proliferation mediated by growth factor receptor tyrosine kinase activity for example for inhibition of angiogenesis, or vascular smooth muscle cell proliferation in disorders including atherosclerosis, hyperthrophic heart failure and postsurfical restenosis, and of cell proliferation and migration in the treatment of primary tumors and metastasis. Some of the 5,10,15,20-tetraaryl-prophyrins are novel compounds.
Type:
Grant
Filed:
July 18, 2001
Date of Patent:
May 4, 2004
Assignees:
Yeda Research and Development Co. Ltd., Technion Research and Development Foundation Ltd.
Abstract: A piezoelectric device is disclosed, which includes a first element of porous crystalline material, a second element being attached to, or integrally formed with, the first element, and at least one electrode being in electrical contact with the first element, such that subjecting the first element to an electric potential via the at least one electrode results in a strain induced by the first element on the second element. Also disclosed is a piezooptic device which includes a first element of porous crystalline material, a second element being attached to, or integrally formed with, the first element, and a light source, such that subjecting the first element to light originating from the light source results in a strain induced by the first element on the second element.
Type:
Grant
Filed:
February 1, 2002
Date of Patent:
April 27, 2004
Assignee:
Technion Research & Development Foundation Ltd.
Abstract: Apparatus for obtaining 3-Dimensional data of a geometric body for matching, and particularly for use in facial matching, comprises a three dimensional scanner for obtaining three-dimensional topographical data of the body, a triangulator for receiving or forming said data into a triangulated manifold, a geodesic converter, for converting the triangulated manifold into a series of geodesic distances between pairs of points of the manifold, and a multi-dimensional scaler, for forming a low dimensional Euclidean representation of the series of geodesic distances, to give a bending invariant representation of the geometric body. In one variant, matching is carried out by taking the principle eigenvalues from the representation and plotting as co-ordinates in a feature space. Tilted or different expression versions of the same face tend to form clusters in the feature space allowing for matching. The apparatus preferably uses the fast marching method for the triangulated domain to obtain the geodesic distances.
Type:
Application
Filed:
October 31, 2002
Publication date:
April 22, 2004
Applicant:
TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
Inventors:
Alexander Bronstein, Michael Bronstein, Ron Kimmel
Abstract: A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.
Type:
Application
Filed:
February 19, 2003
Publication date:
April 8, 2004
Applicant:
Technion Research & Development Foundation Ltd.
Abstract: The present invention provides a method for the in vitro selection of signaling aptamers comprising the steps of synthesizing a DNA pool, the DNA having a random insert of nucleotides of a specific skewed mole ratio; amplifying the DNA pool; transcribing an RNA pool from the amplified DNA using a fluorescently labeled nucleotide; applying the fluorescently labeled RNA pool to an affinity column to remove the high-affinity fluorescent RNA molecules from the fluorescently labeled RNA pool; obtaining a cDNA pool from the high-affinity fluorescent RNA molecules; repeating the amplification and selection steps on the fluorescent RNA molecules and cloning the fluorescent RNA molecules to yield signaling aptamers. Signaling aptamers comprising DNA molecules are also selected for. Also provided is a signaling aptamer that transduces the conformational change upon binding a ligand to a change in fluorescence intensity of the signaling aptamer.
Type:
Grant
Filed:
October 26, 2001
Date of Patent:
March 16, 2004
Assignee:
Research Development Foundation
Inventors:
Manjula Rajendran, Andrew D. Ellington, Sulay D. Jhaveri
Abstract: The present invention provides an antiproliferative compound having a structural formula
where X and Y independently are oxygen, nitrogen o r sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitriles; R2 and R3 are hydrogen or R4; R4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R6, wherein R6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.
Type:
Grant
Filed:
November 5, 2001
Date of Patent:
March 9, 2004
Assignee:
Research Development Foundation
Inventors:
Bob G. Sanders, Kimberly Kline, Weiping Yu
Abstract: The present invention provides a method of increasing the cellular expression of a gene in a biological tissue after delivery of said gene to an animal, comprising the step of: administering to said animal a pharmacologically effective dose of a glucocorticoid in an amount sufficient to increase the cellular expression of said gene. Also provided is a various method of treating a pathophysiological state in a human by increasing cellular expression of a gene after delivery of said gene into a biological tissue of an animal in need of such treatment, comprising the step of: administering to said animal a pharmacologically effective dose of a glucocorticoid in an amount sufficient to increase the cellular expression of said gene.
Type:
Application
Filed:
September 19, 2003
Publication date:
March 4, 2004
Applicant:
Research Development Foundation
Inventors:
Lindsay Schwarz, Vernon Knight, Jennifer Johnson
Abstract: Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-&bgr; receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary.
Type:
Grant
Filed:
December 15, 2000
Date of Patent:
February 17, 2004
Assignee:
Research Development Foundation
Inventors:
Wylie Vale, Kathy A. Lewis, Peter C. Gray, Louise M. Bilezikjian, Amy L. Blount
Abstract: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.
Abstract: The present invention provides a method of screening individuals at risk for developing diseases caused by trinucleotide repeat sequence instability. Specifically, the present invention is drawn to screening individuals at risk for developing autosomal dominant spinocerebellar ataxia type 6 by determining the length of a CAG trinucleotide repeat in the &agr;1A calcium channel gene of the individual. In addition, there is provided a method of identifying genes which are disease-causing due to trinucleotide repeat sequence instability by large scale genotyping.
Abstract: A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediyne, aza-enyne allene, or an aza-diallene. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acids. In addition it is believed that these compounds may undergo chemical reactions in the presence of a nucleic acid to generate reactive intermediates that cleave nucleic acids.
Abstract: The present invention provides a multi-meandered antenna with multiple bands and single input to be used in a vehicle wireless communication environment, which comprises: an input end, coupled to a metal body of said vehicle for getting wireless signals, and at least one meandered antenna, coupled to said input end for transmitting or receiving said wireless signals. Whereby, said multi-meandered antenna with multiple bands and single input can satisfy the various wireless communication requirements of said vehicle after combining.
Type:
Application
Filed:
July 14, 2003
Publication date:
January 22, 2004
Applicant:
Yen Tjing Ling Industrial Development Foundation
Inventors:
Hsueh-Jyh Li, Chang-Fa Yang, Jen-Hsun Li
Abstract: Immunoconjugates of an antibody to a 22 KD breast tumor associated antigen were prepared. Cytotoxic immunoconjugates such as gelonin-15A8 antibody conjugate are useful for treating proliferative cell diseases such as breast carcinoma and cervical carcinoma as well as other tumors which bear the 15A8 antigen. Detectably labeled compositions for diagnosis of such diseases are also disclosed.
Type:
Grant
Filed:
September 24, 1993
Date of Patent:
December 30, 2003
Assignee:
Research Development Foundation
Inventors:
Michael G. Rosenblum, Renato Dulbecco, W. Ross Allen
Abstract: The present invention is directed to the cloning, sequencing and expression of homologous immunoreactive 28-kDa protein genes, p28-1, -2, -3, -5, -6, -7, -9, from a polymorphic multiple gene family of Ehrlichia canis. Further disclosed is a multigene locus encoding all nine homologous 28-kDa protein genes of Ehrlichia canis. Recombinant Ehrlichia canis 28-kDa proteins react with convalescent phase antiserum from an E. canis-infected dog, and may be useful in the development of vaccines and serodiagnostics that are particularly effective for disease prevention and serodiagnosis.
Type:
Grant
Filed:
March 16, 2001
Date of Patent:
December 9, 2003
Assignee:
Research Development Foundation
Inventors:
David H. Walker, Xue-Jie Yu, Jere W. McBride
Abstract: The present invention provides a method of increasing the cellular expression of a gene in a biological tissue after delivery of said gene to an animal, comprising the step of: administering to said animal a pharmacologically effective dose of a glucocorticoid in an amount sufficient to increase the cellular expression of said gene. Also provided is a various method of treating a pathophysiological state in a human by increasing cellular expression of a gene after delivery of said gene into a biological tissue of an animal in need of such treatment, comprising the step of: administering to said animal a pharmacologically effective dose of a glucocorticoid in an amount sufficient to increase the cellular expression of said gene.
Type:
Grant
Filed:
September 6, 1996
Date of Patent:
December 2, 2003
Assignee:
Research Development Foundation
Inventors:
Lindsay Schwarz, Vernon Knight, Jennifer Lee Johnson